IPXL Impax Laboratories, Inc.

15.85
+0.05  (0%)
Previous Close 15.80
Open 15.85
Price To book 2.09
Market Cap 1.13B
Shares 71,597,000
Volume 879,877
Short Ratio 1.32
Av. Daily Volume 2,481,290

Drug Information

Drug catalyst information is displayed when you hover over the stage bar graph.

CRL January 21 2013. Approved Jan 8 2015
IPX066
Parkinson's

Latest News

  1. Impax to Present at the UBS Global Healthcare Conference
  2. Edited Transcript of IPXL earnings conference call or presentation 10-May-17 12:30pm GMT
  3. ETFs with exposure to Impax Laboratories, Inc. : May 15, 2017
  4. These Stocks Show Change of Direction
  5. Impax Laboratories, Inc. :IPXL-US: Earnings Analysis: Q1, 2017 By the Numbers : May 12, 2017
  6. Impax (IPXL) Q1 Earnings Miss, Stock Up on Cost Savings Plan
  7. Impax to Present at the Bank of America Merrill Lynch Healthcare Conference
  8. Investor Network: Impax Laboratories, Inc. to Host Earnings Call
  9. Impax Labs reports 1Q loss
  10. Impax Reports First Quarter 2017 Financial Results
  11. Merck cholesterol drug Vytorin faces competition from Impax, Teva generics
  12. FDA approves Impax generic of Merck's cholesterol drug Vytorin
  13. Impax Announces FDA Approval and Launch of a Generic Version of Vytorin® (Ezetimibe/Simvastatin Tablets)
  14. Vetr Crowd Urges Sell For Impax Laboratories
  15. Impax to Present Data on Rytary® (Carbidopa and Levodopa) Extended-Release Capsules, Zomig® (Zolmitriptan) Nasal Spray and Investigational Drug IPX203 at the 2017 American Academy of Neurology® Annual Meeting
  16. Blog Coverage AbbVie's HCV Regimen Achieves 99% Cure Rate in Phase III Study
  17. Impac Secured Assets Corp. Mortgage Pass-Through Certificates, Series 2006-5 -- Moody's downgrades Impax's CFR to B2, outlook stable
  18. Impax to Report First Quarter 2017 Results on May 10, 2017
  19. Impax (IPXL) Up 35.3% Since Earnings Report: Can It Continue?
  20. Impax Announces Favorable Ruling Regarding Patent Validity for Zomig® (zolmitriptan) Nasal Spray

SEC Filings

  1. 8-K - Current report 17852415
  2. 10-Q - Quarterly report [Sections 13 or 15(d)] 17830268
  3. 8-K - Current report 17828422
  4. DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material 17742819
  5. DEF 14A - Other definitive proxy statements 17742800
  6. 8-K - Current report 17742669
  7. 8-K - Current report 17717551
  8. 8-K - Current report 17715443
  9. 10-K - Annual report [Section 13 and 15(d), not S-K Item 405] 17654358
  10. 8-K - Current report 17651378